Cell：母乳中的骨桥蛋白通过肠道微生物促进婴儿免疫发育，帮助抵御感染疾病
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - A Cell paper (Aug 3, 2026) from QIMR Berghofer and the University of Queensland shows that osteopontin (OPN) in breast milk reshapes the infant gut microbiome to drive dendritic cell (DC) hematopoiesis in liver and lung, conferring tolerance to severe lower respiratory infection (sLRI). It matters because it identifies a specific milk protein — already added to some infant formulas — with a defined mechanistic pathway for early-life immune protection. (Note: this is biomedical research, not AI content.)
- Cross-fostering OPN+/+ newborn mice to OPN−/− dams removed milk-derived OPN; pups became susceptible to viral (pneumonia virus of mice, the murine RSV homolog) and bacterial lower respiratory infection due to disrupted liver and lung DC hematopoiesis.
- Oral OPN supplementation reduced disease severity, correlating with increased gut Lactobacillus abundance and elevated serum 3-phenyllactic acid (PLA), a PPARγ agonist.
- PLA or the PPARγ agonist rosiglitazone restored lung DC hematopoiesis via airway epithelium-derived CCL25-mediated recruitment of lymphoid-myeloid progenitors; depleting pDCs, neutralizing stem cell factor, or airway-epithelial Flt3L knockout abolished the effect.
- PLA also prevented the increased sLRI susceptibility caused by maternal antibiotic exposure, and human data cited include a 280-participant trial where bovine OPN-supplemented formula lowered fever incidence at 4 months.
Sources (1)
Cell：母乳中的骨桥蛋白通过肠道微生物促进婴儿免疫发育，帮助抵御感染疾病
TL;DR - A Cell paper (Aug 3, 2026) from QIMR Berghofer and the University of Queensland shows that osteopontin (OPN) in breast milk reshapes the infant gut microbiome to drive dendritic cell (DC) hematopoiesis in liver and lung, conferring tolerance to severe lower respiratory infection (sLRI). It matters because it identifies a specific milk protein — already added to some infant formulas — with a defined mechanistic pathway for early-life immune protection. (Note: this is biomedical research, not AI content.)
- Cross-fostering OPN+/+ newborn mice to OPN−/− dams removed milk-derived OPN; pups became susceptible to viral (pneumonia virus of mice, the murine RSV homolog) and bacterial lower respiratory infection due to disrupted liver and lung DC hematopoiesis.
- Oral OPN supplementation reduced disease severity, correlating with increased gut Lactobacillus abundance and elevated serum 3-phenyllactic acid (PLA), a PPARγ agonist.
- PLA or the PPARγ agonist rosiglitazone restored lung DC hematopoiesis via airway epithelium-derived CCL25-mediated recruitment of lymphoid-myeloid progenitors; depleting pDCs, neutralizing stem cell factor, or airway-epithelial Flt3L knockout abolished the effect.
- PLA also prevented the increased sLRI susceptibility caused by maternal antibiotic exposure, and human data cited include a 280-participant trial where bovine OPN-supplemented formula lowered fever incidence at 4 months.